AC
ELEV

Annandale Capital’s Elevation Oncology ELEV Stock Holding History

Annandale Capital’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,000
Closed -$27K – 144
2023
Q4 		$27K Hold
50,000
– – 0.01% 138
2023
Q3 		$33K Hold
50,000
– – 0.01% 132
2023
Q2 		$76K Hold
50,000
– – 0.02% 131
2023
Q1 		$95K Hold
50,000
– – 0.03% 126
2022
Q4 		$48K Buy
50,000
+20,000
+67% +$20.3K 0.02% 130
2022
Q3 		$34K Buy
+30,000
New +$37.8K 0.01% 132

Other funds holding ELEV

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Annandale Capital's ELEV Position: Q1 2024 in Review

Annandale Capital sold out of Elevation Oncology (ELEV) in Q1 2024, closing a stake of 50,000 shares — an estimated $27K sold.

Annandale Capital first reported a position in ELEV in Q3 2022 and held it in 6 quarters. The position peaked at $95K in Q1 2023. 63 funds tracked by Wall St. Rank hold ELEV as of Q1 2024.

  • Annandale Capital reported no remaining Elevation Oncology position as of Q1 2024 after selling out during the quarter.
  • Annandale Capital sold 50,000 Elevation Oncology shares in Q1 2024, an estimated $27K.
  • Annandale Capital first reported a position in Elevation Oncology in Q3 2022 and held it in 6 quarters.
  • Annandale Capital's Elevation Oncology position peaked at $95K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2024.

Based on Annandale Capital's 13F filing for Q1 2024, filed 15 May 2024.